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Abstract Serotonin reuptake inhibitors (SRIs) are widely
used drugs in the treatment of depression and anxiety dis-
orders. Although SRIs are generally regarded as safe drugs
with relatively few side effects, literature suggests that high
concentrations of SRIs may alter immune function. We
investigated whether high-dose treatment with fluoxetine
was able to suppress acute graft-versus-host disease
(GvHD) in a MHC-matched, minor histocompatibility anti-
gen mismatched murine bone marrow transplantation mod-
el. We found that high doses fluoxetine induce a significant
reduction of clinical symptoms and increase survival of
these animals. The amelioration of clinical GvHD was ac-
companied by a reduced expansion of alloreactive T cells.
We further analyzed the direct in vitro effect of six SRIs on the
viability and proliferation of human T cells and found an anti-
proliferative and pro-apoptotic effect that was significantly
larger in activated than in resting T cells. We discuss these
results in the light of potential future exploration of SRIs as a
novel class of T cell immunosuppressive drugs.
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Introduction
Serotonin reuptake inhibitors (SRIs) belong to the most
frequently prescribed drugs worldwide. While originally
introduced to treat major depressive disorder, they have
proven to be effective in a number of psychiatric and neu-
rological conditions such as obsessive-compulsive disorder,
panic disorder and generalized anxiety disorder (Hughes et
al. 1999; Vaswani et al. 2003). In the past decades, it has
become clear that SRIs not only affect biological mechanisms
within the central nervous system, but also have an influence
on immunity. Evidence exists that SRIs may attenuate auto-
immune responses in experimental autoimmune encephalo-
myelitis, collagen-induced arthritis, murine allergic asthma
and contact hypersensitivity reaction (Vollmar et al. 2009;
Taler et al. 2011; Yuan et al. 2012; Sacre et al. 2010;
Roumestan et al. 2007; Kubera et al. 2012). Hypothesizing
that SRIs may hold potential as a novel class of immunosup-
pressive drugs, the first aim of this study was to determine
whether SRIs could also suppress alloreactive Tcell responses
in murine graft-versus-host disease (GvHD). Using a MHC-
matched, minor histocompatibility antigen (miHA)-mismatched
model of allogeneic bone marrow transplantation (BMT), we
deliver proof-of-concept evidence that SRIs may also attenuate
murine GvHD.
The immunological alterations induced by SRIs in animal
models of disease are reflected in the direct effects these drugs
exert on lymphocytes. Several in vivo and in vitro reports
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have demonstrated a negative effect of SRIs on mitogen-
induced lymphocyte proliferation (Berkeley et al. 1994;
Edgar et al. 1998; Edgar et al. 1999; Pellegrino and Bayer
1998, 2000; Taler et al. 2008; Fazzino et al. 2008), pro-
inflammatory cytokine secretion (Taler et al. 2008; Taler et
al. 2007; Xia et al. 1996; Maes et al. 1999; Kubera et al. 2001)
and lymphocyte viability (Taler et al. 2008; Taler et al. 2007;
Xia et al. 1997). Although it is clear that several research
groups have investigated the anti-proliferative and pro-
apoptotic effects of SRIs, variation in the SRIs studied,
the concentrations used and the experimental read-out
hampers comparison between studies and interpretation of
results. Therefore, a comprehensive study comparing the
anti-proliferative and pro-apoptotic effects of all available
SRIs in both activated and resting human lymphocytes
would contribute to our understanding of the potential
immunomodulatory effects of SRI treatment. Thus, the
second aim of this study was to determine and compare
the direct in vitro effects of six different SRIs used in
clinical practice (paroxetine, fluoxetine, sertraline,
fluvoxamine, citalopram and venlafaxine) on the viability
and proliferation of lymphocytes from healthy human sub-
jects. We found clear in vivo and in vitro evidence that
SRIs may alter T cell responsiveness.
Materials and methods
Reagents
Citalopram, sertraline, fluvoxamine and venlafaxine were
purchased from Sigma Aldrich (St-Louis, MO, USA).
Paroxetine was purchased from Fagron (Nieuwerkerk a/d
IJssel, The Netherlands), and fluoxetine from ABC
chemicals (Wouters-Brakel, Belgium). For animal experi-
ments, fluoxetine was dissolved in PBS. For in vitro exper-
iments, the drugs were diluted in RPMI-1640, supplemented
with 10% heat-inactivated fetal bovine serum, 1% glutamine
and 1% penicillin/streptomycin (100 U/ml penicillin G;
100 μg/ml streptomycin). All cell culture reagents were
purchased from Invitrogen (Carlsbad, CA, USA).
Animals
Ten- to 12-week old female AKR (H-2k, Thy1.1, Mls1a/2b)
mice were used as recipients and 6- to 8-week old C3H
(H-2k, Thy1.2, Mls1b/2a) mice as donors. Mice were pur-
chased from Harlan BV, The Netherlands. Recipients were
housed in groups of four or five in individually ventilated
cages. Animals were fed standardised pellet chow and wa-
ter, decontaminated by UV irradiation or by acidification.
All experiments were approved by the Ethical Committee
for Animal Science of the University of Leuven.
GvHD model and SRI treatment
Bone marrow (BM) cells were obtained by flushing RPMI
containing 1% heparin through the shafts of the femurs and
tibia of C3H donor mice. T cell depletion was performed
using cytotoxic complement-fixing anti-Thy1.2 antibody
and low toxic rabbit complement (Serotec, Oxford, United
Kingdom) as described previously (Billiau et al. 2002).
AKR recipient mice received a single dose of 9.5 Gy total
body irradiation on day -1. Within 24h after completion of
irradiation, either 5×106 T cell depleted BM (BMT only) or
5×106 T cell depleted BM in combination with 50×106
spleen cells (BMT + SPL) were injected into a tail vein in
a total volume of 250 μl. Recipient mice were treated with
20 mg/kg fluoxetine IP 2×/day at the day of transplantation,
1×/day for the following 11 days, and 3×/week for the rest
of the experiment. Control animals received vehicle (PBS)
only. The ‘BMT only’ group did not receive any treatment.
GvHD scoring
Animals were inspected on a daily basis. Signs of GvHD
typically observed in this model are ruffled fur and hunched
posture, lethargy, inflammation of the eyes, weight loss and
diarrhea (Sefrioui et al. 2000; Billiau et al. 2002). The mice
were weighed and scored for GvHD once weekly, using a
GvHD scoring system previously described in this model
(Fevery et al. 2007). Each parameter received a score as
followed: 0 = normal, 1 = mild, 2 = moderate, 3 = severe.
For body weight, the following scoring system was used:
0 = 100–90%, 1 = 90–80%, 2 = 80–70%, 3 = <70% of initial
body weight. The maximum score was 15. Mice that
succumbed to GvHD received the maximum score of 15.
Donor T cell chimerism and host-reactive donor T cell
frequency
The percentage of donor T lymphocytes in peripheral blood
was determined by flow cytometry, based on the differential
expression of Thy1.2 (donor) and Thy1.1 (recipient).
Following red blood cell lysis with NH4Cl, cells were la-
belled with FITC- or PE-conjugated anti-Thy1.1 and anti-
Thy1.2 (Serotec, Oxford, UK). The frequency of host-
reactive TCR-Vβ6+ T cells was determined as a parameter
of in vivo alloreactive T cell expansion (Billiau et al. 2002;
Sefrioui et al. 2000). Cells were labelled with APC-, PE- or
PerCP-conjugated antibodies against CD3 and TCR-Vβ6
(BD Biosciences, Erembodegem, Belgium).
In vitro apoptosis assay
Human peripheral blood mononuclear cells (PBMCs) from
six healthy volunteers were obtained by Ficoll density
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centrifugation. T cells were isolated from PBMCs using a
human T cell enrichment kit (STEMCELL technologies,
Vancouver, Canada) according to the manufacturer’s in-
structions. T cell purity was determined by staining with
anti-CD3 PECy5 and flow cytometric analysis and was in
each experiment greater than 97%. Anti-CD3/CD28 beads
(Dynal Biotech ASA, Oslo, Norway) were added in a 1:1
ratio and 2×105 cells were seeded per well in a total volume
of 200 μl. After a 24h-incubation in the presence of SRIs,
cells were stained with 0.5 μl annexin V-FITC and 10 μl
propidium iodide (PI) (BD Pharmingen, San Diego, CA,
USA). Activation status was determined by staining with
anti-CD69 PECy7 (eBiosciences, San Diego, CA, USA).
In vitro proliferation assay
Isolated PBMCs from six healthy volunteers were stained
with 10 μM carboxy-fluorescein diacetate succinimidyl es-
ter (CFSE) (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions. Subsequently, cells were
activated with 4×105 anti-CD3/CD28 beads per 106
PBMCs. 25×104 PBMCs were seeded per well in a total
volume of 250 μl and incubated for 6 days in the presence of
SRIs. Thereafter, cells were stained with anti-CD3 PECy5
(eBiosciences, San Diego, CA, USA). All analyses were
performed on a Cytomics FC500 flow cytometer
(Beckman Coulter, Miami Florida). Dead cells were exclud-
ed based on FSC-SSC properties. For CD3+ T cells, a
proliferation index was calculated according to the follow-
ing formula (Roederer 2011):
Proliferation index ¼
P
i
0NiP
i
0
Ni
2i
with i ¼ generation number 0 is the undivided populationð Þ and
Ni ¼ the number of events in generation i:
All in vitro experiments were approved by the Ethical
Committee of the Ghent University Hospital.
Statistics
In vivo experiments. The Gehan-Breslow-Wilcoxon test
was used to estimate the level of significance of the
difference in survival between treatment groups. The
Wilcoxon signed ranks test was used to identify statisti-
cally significant differences for GvHD scores and flow
cytometry data between treatment groups. In vitro exper-
iments. Wilcoxon signed ranks tests were used to identify
statistically significant differences between treatment and
control, and between activated and resting T cells.
Results were considered statistically significant if one-
tailed p-values were <0.05.
Results
Fluoxetine delays the onset and attenuates the severity
of GvHD
An established model of acute GvHD in a MHC-matched
miHA-mismatched mouse strain combination was used
(Sefrioui et al. 2000; Billiau et al. 2002). AKR recipient
mice carry the Mtv-7 retrovirus which encodes the Mls-1
antigen, leading to deletion of TCR-Vβ6+ T cells. C3H
donor mice do not carry the Mtv-7 virus and therefore
TCR-Vβ6+ T cells are retained in these mice. In this model,
donor and recipient mice differ in their expression of the
Mtv7-genome, which has been shown to be associated with
a highly increased rate and severity of GvHD (Miconnet et
al. 1995).
An IP dose of 20 mg/kg fluoxetine was administered twice
at the day of transplantation in order to achieve high enough
plasma levels to prevent alloreactive T cells to initiate an
immune reaction. To prevent alloreactivity during the imme-
diate posttransplant period (day 2–12), fluoxetine was admin-
istered 1×/day. In this period, the frequency and severity of
GvHD is higher, possibly because of overstimulation of host-
reactive T cells by the remnants of the cytokine storm elicited
by the conditioning regimen (Antin and Ferrara 1992). In our
murine model, cytokine mRNA expression is diminished by
day ten after irradiation (Billiau et al. 2001). During the rest of
the experiment, a maintenance dose was given 3×/week. A
20 mg/kg IP dose was chosen as this dose gives rise to a
plasma concentration of 4 μM (Holladay et al. 1997), a
concentration that showed optimal anti-proliferative effect in
preliminary murine mixed lymphocyte reactions without in-
ducing cytotoxicity (data not shown).
Throughout the course of the experiment, mice were ob-
served daily for clinical symptoms of GvHD and the GvHD
score was recorded weekly. Mice that were treated with vehi-
cle developed typical symptoms of GvHD (score > 2) after
4 weeks, whereas fluoxetine-treated mice only showed clini-
cal signs of illness after 8 weeks (Fig. 1a). Although
fluoxetine-treated mice did develop clinical symptoms in the
course of the experiment, GvHD was less severe in this group
compared to vehicle-treated mice (p<0.0001). Control mice
receiving either BMT+SRI (n=6), BMT+vehicle (n=7) or
BMTonly (n=5) did not develop clinical signs of GvHD (data
not shown).
Fluoxetine reduces GvHD lethality
In Fig. 1b, the survival of AKR mice after transplantation of
5×106 C3H BMT only or together with 50×106 SPL cells
and treated with 20 mg/kg fluoxetine or vehicle is shown.
Whereas only 4/12 (33.3%) animals from the vehicle-treated
group survived 6 months after transplantation, 7/13 (53.8%)
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mice survived in the fluoxetine-treated group (p=0.05).
Control mice receiving either BMT+SRI (n=6) (data not
shown), BMT+vehicle (n=7) (data not shown) or BMT only
(n=5) all survived until the end of the experiment.
Fluoxetine does not interfere with engraftment of cells
In order to determine whether fluoxetine interferes with the
engraftment of the allogeneic cells, peripheral blood donor
T cell chimerism was determined at week 8 after transplan-
tation, a time point at which donor T cell chimerism – in the
absence of GvHD - can be expected to be near-complete
(Billiau et al. 2002). Thy1.2 and Thy1.1 expression was
used to discriminate between donor- and recipient-derived
lymphocytes, respectively. Both fluoxetine-treated and
vehicle-treated mice showed a donor T cell chimerism of
more than 99%, indicating that the efficiency of the stem
cell transplantation was equal in both groups and was not
negatively influenced by fluoxetine. Consistent with previ-
ous work in this model, donor T cell chimerism of the ‘BMT
only’ group was around 90% (Fig. 2a).
Fluoxetine reduces the expansion of donor-type host-reactive
T cells
In murine GvHD models involving Mls-disparate mouse
strains, GvHD has been shown to be associated with expan-
sion of donor-type T cells bearing TCR Vβ chains that are
specific for host-type Mls antigens (Sefrioui et al. 2000;
Johnson et al. 1995; Billiau et al. 2002). Accordingly,
GvHD in C3H-AKR chimeras is associated with an expansion
of TCR-Vβ6+ Tcells (Sefrioui et al. 2000; Billiau et al. 2002).
In order to determine whether fluoxetine suppressed the ex-
pansion of these host-reactive T cells, we determined the
frequency of CD3+Vβ6+ T cells in peripheral blood of chi-
meras at week 8 after bone marrow transplantation, a time
point at which control mice showed clear GvHDwhereas SRI-
treated mice were still free of GvHD clinical symptoms (score
≤ 2). The results are shown in Fig. 2b. Fluoxetine-treated mice
showed a significantly lower percentage of peripheral blood
CD3+Vβ6+ T cells than vehicle-treated mice (p=0.016), in-
dicating that the beneficial effect of fluoxetine on GvHD is
indeed associated with a reduced expansion of host-reactive T
cells.
Activated human T cells are more sensitive to SRI-induced
apoptosis than resting T cells
We next explored whether the observed effect of SRIs on the
T cell response in murine GvHD can be due to a direct effect
on T cells. To this end we investigated the viability of both
resting and activated T cells, obtained from 6 healthy human
volunteers, when exposed to SRIs in vitro. In this study, we
did not only investigate the effects of fluoxetine, but incor-
porated the most frequently used SRIs (paroxetine, sertra-
line, citalopram, fluvoxamine and venlafaxine). T cells were
stimulated using anti-CD3/CD28 beads and the activation
status of the cells was confirmed by the expression of CD69.
More than 80% of the T cells were CD69 positive after a
24h-incubation with anti-CD3/CD28 beads (‘activated T
cells’). In contrast, less than 2% of the T cells that were
not stimulated expressed CD69 (‘resting T cells’).
Fig. 1 Effect of fluoxetine on GvHD score and survival. AKRmice were
irradiated with 9.5 Gy on day -1 and transplanted with 5×106 C3H BM
only or together with 50×106 SPL cells on day 0. Mice were treated with
20mg/kg IP fluoxetine or vehicle 2×/day on the day of transplantation, 1×/
day for the following 11 days and 3×/week for the rest of the experiment. a
mean ± SEM GvHD scores from BMT+SPL+SRI group (n=13) and
BMT+SPL+vehicle group (n=12). GvHD score was based on five param-
eters, each receiving a score of 0–3: ruffled fur and hunched back,
inflammation of the eyes, weight, diarrhea and lethargy. b Survival curve.
Results are the percentage survival from BMT+SPL+SRI (n=13),
BMT+SPL+vehicle (n=12) and BMT only (n=5) groups. Results are
pooled data from two different experiments
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To detect apoptotic cells, annexin V and PI staining
was performed. PI staining correlated well with annexin
V data (correlation coefficients were typically >0.99) and
therefore, only annexin V data were further used for data
analysis. The mean percentage annexin V+ cells in control
samples (n=6) was 4.05 ± 1.72% for resting T cells and 5.99 ±
4.65% for activated T cells. In order to compare apoptosis
rates in resting and activated T cells, annexin V+ percentages
obtained in control samples were subtracted from the individ-
ual percentages determined in the test samples. Thus, differ-
ences in SRI-induced apoptosis found between resting and
activated T cells cannot be ascribed to differences in basal
apoptosis.
Detailed analysis of the annexin V+ T cell percentages
revealed that paroxetine (p= 0.016) and sertraline (p=0.031)
significantly induced apoptosis in activated T cells at 5 μM,
while for the other SRIs, no apoptosis could be detected at this
concentration. For fluoxetine on the other hand, apoptosis
could be detected at concentrations of 10 μM or higher in
activated T cells (p=0.016). Fluvoxamine showed a similar
effect, but at a higher concentration range: apoptosis started to
appear at concentrations of 50 μM (p=0.016). Citalopram
only induced a slight increase in apoptotic cells, and statistical
significance was reached at 100 μM only (p=0.016). No
apoptosis could be detected after treatment with venlafaxine
at concentrations up to 100 μM.
Interestingly, activated T cells were more sensitive to
the apoptotic effect compared to resting T cells (Fig. 3).
Paroxetine, fluoxetine, sertraline and fluvoxamine induced
significantly more apoptosis in activated T cells than in
resting T cells. For paroxetine, already the lowest tested
concentration (5 μM) induced significantly more apoptosis
in the activated cells (p=0.031). This difference was
maintained with higher concentrations (10 μM, p=0.016 and
20 μM, p=0.016). For fluoxetine (p=0.016) and sertraline
(p=0.031), a significantly higher effect could be detected in
the activated T cells at 10 μM. Fluoxetine maintained this
significantly higher induction of apoptosis at 20 μM
(p=0.031). In contrast, sertraline did not exert a differential
effect on activated and resting T cells at the highest
concentration tested (20 μM). The absence of a significant
difference at this concentration might be due to an in-
creased cytotoxicity of this high concentration of sertra-
line. Fluvoxamine induced significantly more apoptosis in
the activated T cells at the 2 highest concentrations tested
(50 μM, p=0.016 and 100 μM, p=0.016). Citalopram did not
exert a differential effect on activated versus resting T cells,
however this may be due to the fact that citalopram only induced
a very low percentage of apoptosis in both cell populations. No
apoptosis could be detected after treatment with venlafaxine in
concentrations up to 100 μM.
SRIs can inhibit T cell proliferation at concentrations
that do not affect T cell viability
In order to evaluate the effect of SRIs on T cell proliferation,
PBMCs from healthy volunteers were labelled with CFSE,
activated with anti-CD3/CD28 beads and incubated for 6 days
in the presence of SRIs. The amount of T cells in each cell
cycle was determined by flow cytometry and the results were
expressed as a proliferation index.
All SRIs tested decreased the proliferation index in a
concentration-dependent manner (Fig. 4). Paroxetine
exerted an anti-proliferative effect at 10 μM (p=0.016).
Fluoxetine and sertraline significantly decreased the pro-
liferation index at concentrations as low as 1 μM
(p=0.018 and p=0.047 respectively). Fluvoxamine and
citalopram significantly decreased T cell proliferation at
2 μM (lowest dose tested, p=0.029 and p=0.016 respec-
tively). For venlafaxine, higher doses were needed in
order to reduce T cell proliferation: a significant decrease
for venlafaxine was detected only at 20 μM (p=0.047).
Importantly, the SRI concentrations needed to reduce T
cell proliferation were, except for paroxetine, below those
Fig. 2 Donor chimerism and
alloreactivity. a Percentage
donor T cell chimerism in
peripheral blood lymphocytes,
determined by Thy1.1 (recipient)
and Thy1.2 (donor) positivity. b
percentage alloreactive
CD3+Vβ6+ T cells. Results are
mean ± SEM from 5 animals in
BMT+SPL+SRI and BMT only
group and from 4 animals in
BMT+SPL+vehicle group.
Statistically significant
differences are depicted with *
(one-tailed p<0.05). NS = not
significant
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inducing apoptosis in activated and/or resting T cells
(gray background in Fig. 4).
The strongest decrease in T cell proliferation was
induced by sertraline. Whereas a 5 μM concentration
only slightly affected the viability of resting T cells (an
increase of 1.78 ± 1.38% annexin V+ cells was observed
as compared to controls), this concentration also dramatically
reduced the proliferation of activated Tcells (a mean reduction
of 39.4% was found). At even higher concentrations,
proliferation was almost completely inhibited, but in this
concentration range, also the viability of both resting and
activated T cells was affected.
We clearly documented that fluoxetine treatment is able
to suppress in vivo allo-activated T cell responses and sup-
press clinical GvHD in a mouse model. Acute GvHD was
induced in C3H → AKR radiation bone marrow chimeras,
according to a previously validated model (Sefrioui et al.
2000) and mice were treated either with a high-dose fluox-
etine regimen, or with vehicle. Further, we provided a com-
prehensive study comparing the anti-proliferative and pro-
apoptotic effects of all available SRIs in both activated and
resting human lymphocytes. We clearly demonstrated that in
vitro exposure of human T cells to SRIs affects their respon-
siveness and viability.
Fig. 3 Apoptotic effect of SRIs on activated and resting T cells. In
vitro activated and resting T cells were incubated for 24h with 0–
20 μM paroxetine, 0–20 μM fluoxetine, 0–20 μM sertraline, 0–
100 μM fluvoxamine, 0–100 μM citalopram, 0–100 μM venlafaxine
and subsequently analyzed by annexin V staining. Mean ± SEM
percentages of annexin V+ cells (- control) in activated and resting T
cells are shown (n=6). ( ) = T cells activated with anti-CD3/CD28
beads in a 1:1 bead:cell ratio; ( ) = resting T cells. Statistically
significant differences between activated and resting T cells are
depicted with * (one-tailed p<0.05).
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Discussion
Several lines of evidence exist that SRIs exert an influence
on the immune system. First, in vitro studies have shown a
suppressive effect of SRIs on both rat and human lympho-
cyte proliferation and viability (Pellegrino and Bayer 2000;
Taler et al. 2007). Second, animal studies have demonstrated
that SRIs can attenuate symptoms and inflammatory activity
in selected autoimmune disorders, such as experimental
autoimmune encephalomyelitis (Taler et al. 2011; Vollmar
et al. 2009; Yuan et al. 2012), collagen-induced arthritis
(Sacre et al. 2010), septic shock and allergic asthma
(Roumestan et al. 2007) and contact hypersensitivity reac-
tion (Kubera et al. 2012). These studies suggest that SRIs
might be beneficial in the treatment of autoimmune pathol-
ogies. Third, clinical case reports indicate that SRIs, when
administered in high doses, may influence immune function.
For instance, Reed and Glick report a reactivation of herpes
simplex virus in patients receiving high doses of fluoxetine
(Reed and Glick 1991). Also, a case of recurring sinusitis
was associated with venlafaxine use (Denys et al. 2002).
The above mentioned papers indicate that SRIs might
interfere with pathologically activated autoreactive T cells.
Here, we investigated the role of SRIs in allo-antigen acti-
vated T cells in the course of acute GvHD. Acute GvHD
after allogeneic haematopoietic stem cell transplantation
(alloHSCT) is a cause of extensive morbidity and mortality.
We used a murine MHC-matched, miHA-mismatched bone
Fig. 4 Inhibition of T cell
proliferation by SRIs. PBMCs
were labelled with CFSE,
activated with 4×105 anti-CD3/
CD28 beads per 106 cells and
incubated in the presence of 0–
10 μM paroxetine, 0–10 μM
fluoxetine, 0–10 μM sertraline,
0–50 μM fluvoxamine, 0–
50 μM citalopram, 0–50 μM
venlafaxine for 6 days. Viable
CD3+ cells were gated and
proliferation indices were
calculated based on the number
of cells in each division peak.
Values are expressed as %
inhibition in comparison to
control cells not exposed to
SRIs. Mean ± SEM %
inhibition of 6 individual
experiments are shown.
Concentrations that induce
more than 5% apoptosis in
activated and/or resting T cells
are displayed with gray
background. Statistically
significant differences in
proliferation indices
compared to control cells not
exposed to SRIs are depicted
with * (one-tailed p<0.05)
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marrow transplantation model to investigate whether fluoxe-
tine could reduce GvHD. The MHC-matched, miHA-
mismatched model was chosen in analogy with the human
situation where over 50% of alloHSCT patients receive an
HLA-matched graft (Hurley et al. 2003). In our study, fluox-
etine was found to significantly delay and reduce clinical
symptoms, without interfering with the reconstitution of the
hematopoietic compartment. An improvement in survival rate
was also noted. Furthermore, the percentage of CD3+Vβ6+ T
cells was significantly reduced by fluoxetine, consistent with
an inhibitory effect of this compound on the expansion of
alloreactive T cells. This leads to the assumption that fluoxe-
tine, and possibly also other SRIs can have a beneficial effect
on the outcome of acute GvHD.
In our murine model, a 20 mg/kg fluoxetine dose was
sufficient to delay and reduce clinical symptoms of GvHD.
In comparison, fluoxetine doses used in mice to obtain an
‘antidepressive’ effect are around 10–18 mg/kg (Dulawa et
al. 2004). A single IP dose of 20 mg/kg fluoxetine in mice
gives rise to a serum concentration around 4 μM, measured
30 min after administration (Holladay et al. 1997). Although
plasma concentrations of SRIs in depressive patients are
below 1 μM (Holladay et al. 1997), SRIs are known to have
a wide therapeutic-toxic range in humans and higher dosing
may be achieved without serious adverse effects. Fatal
overdosing with SRIs is very rare and doses up to 30 times
the normal daily doses either do not cause any adverse effects
or only minor effects (Barbey and Roose 1998). Therefore,
plasma concentrations needed for immunomodulation are
expected to be feasible.
Several papers reported on the effect of SRIs on the im-
mune response, but large differences are seen in the type of
SRI, the experimental setup, the test species and the detection
methods. Therefore, the need emerged to correlate all these
previous findings and extend them in order to obtain one
standardized study that gives an overview of the effect of all
clinically available SRIs on both activated and resting T cells.
This study compared the in vitro immunomodulatory effects
of five selective SRIs (paroxetine, fluoxetine, sertraline,
fluvoxamine, citalopram) and one serotonin and noradrenalin
reuptake inhibitor (venlafaxine). We incubated human
PBMCs or purified T cells with SRIs in vitro and determined
the effect on viability and proliferation. SRIs were shown to
exert direct in vitro effects on the viability and proliferation of
T cells. Paroxetine, fluoxetine, sertraline, fluvoxamine and
citalopramwere found to induce apoptosis in activated Tcells,
and this pro-apoptotic effect was significantly lower in resting
T cells. For citalopram, only a slight increase in apoptosis
could be detected and no differential effect on activated versus
resting T cells was found. However, it should be noted that
others showed a substantial pro-apoptotic effect in resting T
cells for citalopram at 180 μM (Xia et al. 1997). Therefore, it
cannot be ruled out that citalopram exerts a differential effect
at concentrations higher than 100 μM. Venlafaxine did not
induce apoptosis in both activated and resting T cells at
concentrations up to 100 μM.
Further, all SRIs were found to reduce T cell proliferation
in a concentration-dependent manner, at concentrations below
those inducing apoptosis (except for paroxetine, which
inhibited T cell proliferation and viability at the same concen-
tration). Since the concentrations needed to significantly re-
duce T cell proliferation are substantially lower than those
affecting resting T cell viability, SRIs could be used to sup-
press proliferation of pathologically activated T cells while at
the same time the repertoire of resting T cells remains unaf-
fected and preserves the capability of reacting to pathogens
and cancer cells at later stages. Moreover, since sertraline
produced a strong anti-proliferative effect while at the same
time retaining resting T cell viability, these data are also
promising for the use of sertraline in GvHD. Further research
on this SRI is therefore requested.
In the central nervous system, SRIs inhibit reuptake of
serotonin through the serotonin transporter (SERT) in the
presynaptic neuron, resulting in increased synaptic serotonin
concentrations (Anderson et al. 2002). Although SERT ex-
pression has also been shown in lymphocytes (Faraj et al.
1994; Fazzino et al. 2008), it is doubted that the immunosup-
pressive effects of SRIs are mediated through the serotonergic
system (Cloonan et al. 2010; Diamond et al. 2006). On the
other hand, it has been suggested that the immunological
effects of SRIs are due to induced changes in several signaling
pathways. SRIs have been demonstrated to interfere with the
activation of the cAMP-dependent protein kinase A (PKA)
pathway and the activation of protein kinase C (PKC), as well
as with the influx of Ca2+ (Maes et al. 2005; Edgar et al. 1998;
Edgar et al. 1999; Kenis et al. 2003). Furthermore, SRI-
mediated induction of apoptosis was accompanied by activa-
tion of the MAPK signaling pathway and downregulation of
the anti-apoptotic factor bcl-2 (Taler et al. 2008). Finally, it has
been suggested that triggering of SERT itself can induce
changes in downstream signaling pathways (Serafeim et al.
2002), thus linking the known affinity of SRIs for SERTwith
the observed changes in signaling pathways. However, the
exact mechanism through which SRIs induce immunosup-
pression requires further investigation.
Our in vitro data indicate that not all SRIs have the same
magnitude of effect in lymphocytes. Whereas paroxetine,
fluoxetine and sertraline exert immunosuppressive effects at
concentrations below 10 μM, fluvoxamine, citalopram and
venlafaxine only exert immunosuppressive effects at 50 μM
or higher. Since the mechanism through which SRIs induce
immunosuppression is not fully understood, it is difficult to
interpret differences in SRIs that might explain the observed
differences in immunological effects. However, assuming that
triggering of SERT is important for the observed effects, the
difference in immunological effects might be explained by the
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different affinity of SRIs for SERT. The three SRIs that exert
the strongest immunosuppressive effects (paroxetine, fluoxe-
tine and sertraline), also have the highest affinity for SERT
(Kd < 1 nM). The SRIs that show less or no immunosuppres-
sive action, fluvoxamine, citalopram and venlafaxine, have
only moderate affinity for SERT (1 nM < Kd < 10 nM)
(Tatsumi et al. 1997). Possibly, the lack of effect for
venlafaxine might as well be explained by the fact that
venlafaxine is a mixed serotonin and noradrenalin reuptake
inhibitor, whereas the other tested SRIs are selective for sero-
tonin. In the case of citalopram, it is known that the R-
enantiomer induces an allosteric modification in SERT, there-
by reducing the binding capacity of the active S-enantiomer
escitalopram (Sanchez 2006). Possibly, the lack of immuno-
suppressive effect seen with the racemic mixture citalopram is
due to the presence of the R-enantiomer.
In conclusion, this study shows that fluoxetine can delay
and reduce clinical symptoms of experimental GvHD, along
with an inhibition of the expansion of alloreactive T cells.
Data on T cells from healthy human subjects show that this
effect may be attributed to a direct anti-proliferative and pro-
apoptotic effect. Given the similar T cell immunosuppres-
sive effects of other SRIs in vitro, the potential application
of these compounds in GvHD should be investigated.
Together with prior studies in EAE and CIA, our data from
a GvHD mouse model support the exploration of the thera-
peutic value of SRI-induced T cell suppression in GvHD
and other immune-mediated disorders. Moreover, the data
underscore the need for further research into the potential
immunomodulatory effects of the therapeutic use of SRIs in
humans.
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